The Pomp Podcast
304: Jo Bhakdi On The Future Of Genomic Sequencing
- Deep genomic sequencing allows detection of somatic mutations in blood samples with unprecedented precision, potentially enabling early cancer detection across 15 cancer types before symptoms appear.
- Quantgene's technology sequences all cell-free DNA copies in a blood sample (thousands to millions) rather than randomly sampling 10–30, dramatically improving sensitivity for rare tumor variants.
- The company employs machine learning, Bayesian analysis, and clinical algorithms layered on top of genomic data to match patient patterns against cohorts and generate actionable recommendations for downstream testing.
- Medical innovation in the US is fundamentally broken because insurance payers prioritize short-term cost reduction over long-term patient outcomes, killing incentives for true breakthrough treatment.
- Quantgene operates on a direct-to-consumer membership model ($200/month for annual somatic testing, $800 one-time for hereditary testing) to align incentives with patient health rather than payer profit.
- Gene editing via CRISPR is scientifically viable today but carries extreme regulatory and safety risks; most of our biological knowledge remains rudimentary, yet breakthroughs can still occur without full mechanistic understanding.